Brief: AB Science Reports Positive Trial Results On Mastinib In Progressive Forms Of Multiple Sclerosis
22/02/2022 17:41
Feb 22 (Reuters) - AB Science SA ABS.PA :
* ANNOUNCED PUBLICATION OF RESULTS FROM ITS POSITIVE PIVOTAL
PHASE
3 TRIAL OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
IN PEER-REVIEWED JOURNAL NEUROLOGY
* STUDY AB07002 MET ITS PRIMARY ANALYSIS ENDPOINT,
DEMONSTRATING A
STATISTICALLY SIGNIFICANT REDUCTION IN CUMULATIVE CHANGE ON
EXPANDED DISABILITY STATUS SCALE SCORE
Source text for Eikon: InGNE31FvPQ
Further company coverage: ABS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041